High Tide Posts Record Q3 2026 Results, Nears $800M Annual Revenue Run Rate
Event summary
- High Tide reported record Q3 2026 revenue of $198.8M, up 33% YoY and 11% sequentially, marking the fastest growth in 15 quarters.
- Adjusted EBITDA reached $16.2M, up 53% YoY, with an 8.2% margin, the highest in 12 quarters.
- Canna Cabana's market share in Canada (excluding BC) increased to 14% from 13% a year ago, with 232 stores operational.
- Remexian distributed a record 10.2 tonnes of medical cannabis in Germany, with revenue of $38.2M in Q3 2026.
- The company secured a $40M senior secured credit facility with Bank of Montreal.
The big picture
High Tide's record Q3 2026 results underscore its dual-engine growth strategy, with Canna Cabana solidifying its retail dominance in Canada and Remexian scaling rapidly in Germany's medical cannabis market. The company's ability to generate substantial free cash flow while investing in growth positions it favorably amid evolving regulatory landscapes, particularly in the U.S. where federal rescheduling could unlock new opportunities. High Tide's strategic focus on capital discipline and operational leverage sets it apart in a competitive cannabis sector.
What we're watching
- Market Expansion
- Whether High Tide can sustain its rapid growth in both Canadian retail and German medical cannabis distribution.
- Regulatory Shifts
- How potential U.S. federal cannabis rescheduling could impact High Tide's strategic opportunities in the adult-use market.
- Operational Efficiency
- The pace at which High Tide can maintain its improving profitability metrics while continuing aggressive growth.
Related topics